Kornimate/medical-research-clean huggingface dataset:
transcranial direct current stimulation in reduction of pain and postoperative opioids consumption after spine surgery

Conditions: Pain, Postoperative

Summary: the experience of pain derives from changes in brain excitability. therefore, modulating the excitability of cortical areas involved in pain processing may become an attractive option in the context of multimodal analgesia during the postoperative period.

the combination of analgesic drugs acting on different mechanisms can potentiate the effects of analgesia. moreover, the understanding of pain physiology at the molecular level supports the development of new specific drugs. indeed, new neurophysiological models of pain processing by the brain are becoming exquisitely refined and are supported by electrophysiological and functional brain imaging studies. one of the interesting concepts that stemmed from these studies is the evidence that the experience of pain is reflected in the central nervous system by widespread activations and excitability changes within a network of interconnected cortical areas and subcortical structures. the network processing of noxious information and their limbic and emotional consequences has been termed the "pain matrix." the continuous observation of the activity and excitability changes that parallel the pain experience led to the development of a new therapeutic approach: the use of central nervous system stimulation techniques.

Eligibility criteria:
inclusion criteria: * able to give informed consent to participate in the study. * postoperative spine surgery patients(discectomy and/or laminectomy). * american society of anesthesiology scores i to ii patients. exclusion criteria: the participant who has any history of: * an adverse reaction to brain stimulation. * a seizure * an unexplained loss of consciousness * a stroke * serious head injury * surgery to their head * any brain related, neurological illnesses * any illness that may have caused brain injury * frequent or severe headaches * metal in your head (outside the mouth) such as shrapnel, surgical clips, or fragments from welding * any implanted medical devices such as cardiac pacemaker's or medical pumps * taking any analgesic medications in the past 24 hours * pregnancy * anyone in your family has epilepsy
predictors of ais unfavorable outcomes

Conditions: Ischemic Stroke; Alteplase Adverse Reaction

Summary: the investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for unfavourable outcomes.

investigators conducted a prospective cohort study between january 2022 and june 2023 and screened 1184 patients presented with ais and received alteplase and included 592 ais patients who met the inclusion criteria and were diagnosed based on a thorough clinical assessment, including a detailed medical history, physical examination and specific brain imaging results and treated with alteplase within four and half hours of stroke onset. the investigators assessed mrs after 90 days via a 10-minute telephone interview. with patients or their primary caregivers to detect the score, all of our patients had baseline mrs of zero. mrs two or less was considered a favourable outcome the study consisted of two distinct groups. the first group consisted of 456 patients who experienced favourable outcomes, while the second group comprised 136 patients who experienced unfavourable outcomes. the investigators evaluated whether the characteristics of ischemic stroke patients, door-to-needle time, and stroke risk factors were predictive variables for unfavourable outcomes.

Eligibility criteria:
inclusion criteria: the investigators enrolled individuals of both genders, aged between 18 and 75, who presented with acute first-ever ischemic stroke and were eligible for thrombolysis. exclusion criteria: * the investigators excluded patients who had not been followed up on for 90 days after enrollment, * those with alteplase contraindications or did not receive the total dose of alteplase due to any reason were excluded * the investigators excluded patients with a known history of persistent or recurrent cns pathology (e.g., epilepsy, meningioma, multiple sclerosis, history of head trauma with a residual neurological deficit). * the investigators excluded patients who had recurrent ischemic stroke diagnosed by appropriate clinical history and/or mri brain findings. * the investigators excluded patients with symptoms of major organ failure, active malignancies, or an acute myocardial infarction within the previous six weeks. * the investigators also excluded pregnant and lactating patients with stroke due to venous thrombosis and stroke following cardiac arrest.

Keywords: alteplase acute ischemic stroke egypt saudi arabia
decision making and psychological outcomes in low-risk papillary thyroid cancer

Conditions: Thyroid Cancer

Summary: this study is being done to understand the decision-making process regarding management choice in low-risk papillary thyroid cancer.


Eligibility criteria:
inclusion criteria: * able to read, write, and communicate in english patients who have been diagnosed with lr-ptc as described above * for aim 1, adults with recently diagnosed lr-ptc who have not yet made a choice between surgery and as * for aim 2, adults with lr-ptc who made a decision about surgery or as at least 3 months prior, but no more than 4 years prior to their routine follow-up visit at which they are being recruited for this study. * active patients of msk and participating institutions exclusion criteria: * patients who have been diagnosed with a tumor greater than 2 cm * patients with clinically suspicious lymphadenopathy in the neck * patients with evidence of gross ete after a biopsy of the papillary thyroid tumor

Keywords: quality of life decision making 17-382
embryo transfer outcomes after vitrification with slush nitrogen compared to liquid nitrogen

Conditions: Infertility

Summary: the proposed study is a single-blind randomized controlled trial which seeks to characterize implantation rates following embryo vitrification and subsequent warming with both slush nitrogen and liquid nitrogen. after warming, implantation rates and pregnancy outcomes will be assessed.

the purpose of this study is to determine if slush nitrogen for embryo vitrification results in higher sustained implantation rates compared to the conventional use of liquid nitrogen. routine ovarian stimulation, oocyte retrieval and embryology care will ensue. all blastocyst stage embryos will be randomized to either the control (liquid nitrogen) or intervention group (slush nitrogen) and vitrified after trophectoderm biopsy has been performed for pgt-a (preimplantation genetic testing for aneuploidy). a single, chromosomally normal embryo will be transferred in a subsequent frozen embryo transfer cycle per routine. implantation rates and pregnancy outcomes will be assessed.

Eligibility criteria:
major inclusion criteria for participants: 1. patients undergoing ivf stimulation cycle with plan for subsequent frozen embryo transfer (fet) 2. patients electing preimplantation genetic testing for aneuploidy (pgt-a) 3. couples electing single embryo transfer (set) major exclusion criteria for participants: 1. all patients who do not voluntarily give their written consent for participation 2. under 18 years old, above 42 years old 3. bmi \> 35 4. maximum day 3 follicle stimulating hormone (fsh) level of 12 or higher 5. anti-mullerian hormone (amh) level less than 1.0 g/ml, tested within previous year 6. total basal antral follicle count less than 6 follicles 7. failed more than one previous fet cycle 8. use of oocyte donation 9. use of gestational carrier 10. presence of hydrosalpinges that communicate with endometrial cavity 11. diagnosis of endometrial insufficiency: prior cycle with maximal endometrial thickness ≤ 6mm, abnormal endometrial pattern (failure to attain a trilaminar appearance), persistent endometrial fluid 12. uncorrected uterine factor infertility (uterine anomaly, submucosal myomas, uterine septum) 13. single gene disorder chromosomal rearrangement requiring a more detailed embryonic genetic analysis 14. male partner with \<100,000 total motile spermatozoa per ejaculate (donor sperm is acceptable) 15. use of surgical procedures to obtain sperm 16. couples undergoing ivf for fertility preservation with no immediate plan for subsequent fet (embryo banking) 17. sex selection 18. personal history of repeated pregnancy loss (two or more unexplained clinical losses defined by presence of fetal heartbeat)
stressors, coping methods and social support in diabetic patients

Conditions: Type 2 Diabetes

Summary: the increasing prevalence of diabetes brought great burden to health status of the investigators population. it is meaningful to investigate the stressor, stress perceived, social support and coping methods in diabetic population in order to provide appropriate assistance to these patients. this study will recruit diabetes patients from out-patient-department and they are invited to complete a questionnaire. the contents of the questionnaire including stress experienced, stress perceived, social support and coping methods. the investigators purpose is to find out the impact of these factors on glycemic controlled and their life quality. the results will be useful to diabetes care team when health education is delivered to patient.

type 2 diabetes patient aged 30-80 y/o under oral hypoglycemic agents with clear conscious enable to answer questions properly who regularly follow up at our metabolism clinic is eligible. patients are asked to complete a questions containing basic personal information, diabetes coping method chinese version (dcm-c)questionnaire, social support and perceived stress scale.

Eligibility criteria:
inclusion criteria: 1. type 2 diabetes 2. aged 30-80 year old 3. under oral hypoglycemic agents 4. clear consciousness exclusion criteria: 1. type 1 diabetes 2. age below 30 and above 80 3. insulin use 4. conscious not clear

Keywords: stress coping methods social support diabetes mellitus
mn-001 in non-alcoholic fatty liver disease, type 2 diabetes mellitus, and hypertriglyceridemia

Conditions: Diabetes Mellitus, Type 2; Hypertriglyceridemia; Non-Alcoholic Fatty Liver Disease

Summary: the design of the phase 2 clinical trial includes the following elements: * multi-center, two-arm, randomized, double-blind, placebo-controlled trial to evaluate mn-001 (tipelukast) vs. placebo in approximately 40 patients in the u.s. * patients will be randomized 1:1 to receive either 500 mg/day of mn-001 (tipelukast) or placebo for 24 weeks. * the co-primary endpoints are (1) change from baseline in liver fat content measured by controlled attenuation parameter (cap) score at week 24, and (2) change from baseline in fasting serum triglycerides at week 24. fibroscan® is a non-invasive, quantitative, and accurate measure of liver fat content commonly used in early phase trials to measure treatment response. * secondary endpoints include safety and tolerability and changes in lipid profile (hdl-c, ldl-c, and total cholesterol).


Eligibility criteria:
inclusion criteria: * fibroscan® cap score ≥ 248 db/m within 8 weeks of randomization. * diagnosis or history of type 2 diabetes mellitus with hemoglobin a1c (hba1c) \>6.5 and ≤10% at screening. * fasting serum triglycerides (tg) at screening \>150 mg/dl * on a stable dose of oral antidiabetic therapy for a minimum of 3 months prior to screening. exclusion criteria: * other causes of chronic liver disease (autoimmune, primary biliary cholangitis, hbv, hcv, wilson's, α-1-antitrypsin deficiency, hemochromatosis, biopsy-proven cirrhosis, hepatocellular carcinoma); * documented history of advanced liver fibrosis * evidence of cirrhosis, hepatic decompensation, portal hypertension including splenomegaly, ascites, encephalopathy and/or esophageal varices; * diagnosis or history of diabetes mellitus type 1; * weight change \>5% within last 3 months of screening visit; * active gastrointestinal disease or history of gastric bypass surgery which could interfere with the absorption of oral medication; * history of clinically significant acute cardiac event within 6 months of screening;
relationship between pfts and pdi in dmd

Conditions: Duchenne Muscular Dystrophy

Summary: a cross-sectional study to explore the relationship between clinically assessed pulmonary function test (pft) measures and transdiaphragmatic (pdi) measures in duchenne muscular dystrophy (dmd) as well as to explore the relationship between sniff nasal inspiratory pressure (snip) and transdiaphragmatic (pdi) measures in duchenne muscular dystrophy.

two small balloons, which are attached to small, flexible tubes, will be put into the esophagus and stomach through your nose. each balloon is about 2 inches long (deflated) and about the width of a pencil tip. to reduce any discomfort with this procedure, lidocaine gel or spray will be put into the subject's nose and administered to the back of the throat before the balloon. in addition, swallowing water during the procedure will help to reduce any gagging sensation and will assure that the balloon goes into the esophagus. proper placement of the catheters will be determined using normal tidal breathing against an occluded mouthpiece with a nose clip. once proper placement is ensured, the catheters will remain in place during your normal pft maneuvers. additionally, while the gastric and esophageal balloon catheters are in place, the subject will be asked to perform a maximal sniff maneuver (snip) while one nostril is occluded with a plug containing a distal pressure measurement catheter to measure airway pressure. the distal end of the pressure catheter will be connected to a hand held pressure meter to display peak pressure and to provide you visual feedback. this maneuver will be performed 10 times.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of duchenne muscular dystrophy exclusion criteria: * inability to follow verbal instructions
study evaluating desvenlafaxine succinate sustained-release (dvs sr) in the treatment of peri- and postmenopausal women with major depressive disorder (dvs 3364)

Conditions: Major Depressive Disorder

Summary: a multicenter, 10-week study to evaluate the efficacy and safety of 50 mg of desvenlafaxine succinate sustained-release formulation (dvs sr) versus placebo in the treatment of peri- and postmenopausal women with major depressive disorder


Eligibility criteria:
inclusion criteria: * peri- and postmenopausal women aged 40 to 70 years who are fluent in both written and spoken english. * postmenopausal status defined by 12 consecutive months of spontaneous amenorrhea; less than 12 consecutive months with at least 6 consecutive months of spontaneous amenorrhea and a pre-baseline follicle-stimulating hormone (fsh) level \>40 miu/ml; or 6 months postsurgical bilateral oophorectomy (with or without hysterectomy). perimenopausal women defined by the presence of any of the following within 6 months before baseline: 1. an absolute change of 7 days or more in menstrual cycle length within 6 months before baseline; 2. a change in menstrual flow amount (2 or more flow categories, eg, from light or moderately light to moderately heavy or heavy); 3. a change in duration (absolute change of 2 or more days); or 4. periods of amenorrhea lasting at least 3 months. * a primary diagnosis of major depressive disorder (mdd) based on the criteria in the diagnostic and statistical manual of mental disorders, fourth edition-text revision (dsm-iv-tr), single or recurrent episode, without psychotic features using the modified mini international neuropsychiatric interview (mini). * a montgomery and asberg depression rating scale (madrs) total score \>=25 at the screening and baseline (day -1) visits and no more than a 5-point improvement from screening to baseline. exclusion criteria: * treatment with dvs sr (pristiq®) at any time in the past and/or venlafaxine, ie, effexor® or effexor xr®, 1 year prior to baseline. * treatment-resistant; eg, in the past 3 years if any of the following treatments have failed: (a) 3 or more previous adequate trials of \>=2 classes of antidepressant medication, (b) electroconvulsive therapy, or (c) 2 adequate trials of psychotherapy (eg, behavior therapy, behavior-marital therapy). * history or current evidence of gastrointestinal disease known to interfere with the absorption or excretion of drugs or a history of surgery known to interfere with the absorption or excretion of drugs. * known presence of raised intraocular pressure or history of narrow-angle glaucoma.
the real world study of zanubrutinib in the treatment of chronic lymphocytic leukemia in china

Conditions: CLL

Summary: this is a multicenter, retrospective real-world study of zanubrutinib in the treatment of chronic lymphocytic leukemia in china


Eligibility criteria:
inclusion criteria: * 1. patients aged ≥18 years old * 2. must have a confirmed diagnosis of chronic lymphocytic leukemia (cll) requiring treatment (iwcll \[international workshop on chronic lymphocytic leukemia\] criteria)； * 3. treatment-naïve or refractory recurrence cll patients who were initiated on zanubrutinib; * 4.prior or current use of zanubrutinib for ≥3 months * 5.at least one follow-up was recorded during zanubrutinib treatment exclusion criteria: -
emergency (red code) cesarean section : maternal and fetal prognosis depending on anesthetic modalities in a level 3 maternity ward

Conditions: Anesthesia Complication

Summary: we try to evaluate whether the type of anesthesia used influences the occurrence of perioperative maternal complications as well as neonatal outcome on emergency (red code) cesarean section. this study occurred in a level 3 maternity ward.


Eligibility criteria:
inclusion criteria: * pregnant women * emergency "code red" cesarean section exclusion criteria: * any other intervention * planned cesarean section

Keywords: c-section, cesarean section, epidural anesthesia, anesthesia complication
modulating effects of lisinopril on sildenafil activity in pulmonary arterial hypertension(pah)( melissa)

Conditions: Pulmonary Arterial Hypertension

Summary: patients with pulmonary arterial hypertension(pah) suffer from chronic shortness of breath, and have impaired survival related to progressive right ventricular failure. abnormal vasoreactivity to nitric oxide(no) plays a role in the pathophysiology of pah. phosphodiesterase type 5 inhibitor (pde5 inhibitors) sildenafil have been shown to be beneficial in pah, but extent of benefit is variable.

the broad aim of this investigation is to determine whether the modulating effect of angiotensin converting enzyme inhibition on vascular smooth muscle responsiveness to the nitric oxide pathway that we have observed in an animal model of congestive heart failure(chf) can be exploited in humans with pah. furthermore, we have identified a group of genes tao kinase i, il-10, rho kinase, raf1, bile acid coenzyme a and fmr1 that are modulated by long-acting angiotensin-converting enzyme inhibitor (acei) in our animal model, and therefore may also be modulated by acei in patients with pah

Eligibility criteria:
inclusion criteria: * age 18-75 * world health organization (who) group i pah with prior documentation of peripheral vascular resistance (pvr) \> 3 wu and wedge(pcw) 16 or less. * who functional class i-iii * 6 minute walk distance 150-575 meters * women of child bearing potential must have a negative pregnancy test and be using effective contraception * receiving therapy with phosphodiesterase-5 inhibitor for pah (sildenafil or tadalafil) for at least 3 months and with stable dose for at least 30 days * if already receiving therapy with endothelin receptor antagonists must have been on therapy for at least 3 months and on stable dose for at least 30 days exclusion criteria: * allergy or intolerance to captopril or other angiotensin converting enzyme inhibitors * systemic systolic blood pressure less than 100 mm hg * therapy with prostanoids (iloprost, treprostinil, epoprostenol) within preceding 3 months * pregnant or breast feeding * creatinine \> 2.0 mg/dl * potassium \> 5.0 meq/dl * unable to provide informed consent * tlc or vc \<60% predicted * untreated obstructive sleep apnea * lvef \< 40% * hb \< 10 mg/dl

Keywords: pulmonary arterial hypertension (pah)
a non-drug study of the suitability of neurocognitive tests and functioning scales for the measurement of cognitive and functioning changes in individuals with down syndrome

Conditions: Down Syndrome

Summary: this non-drug, longitudinal, multi-center, multi-national study will evaluate the suitability of neurocognitive tests and functioning scales for the measurement of cognitive and functioning changes in individuals with down syndrome. tests will be administered at clinic visits in weeks 1, (4) and 24. the duration of the study for each individual will be between 24 and 27 weeks.


Eligibility criteria:
inclusion criteria: * males and females, 12 to 30 years of age, with diagnosis of down syndrome * down syndrome subjects meeting clinical diagnostic criteria for generalized anxiety disorders, major depressive disorders, autism spectrum disorder, attention deficit and hyperactivity disorder can participate in the study provided they are on stable medication for at least 8 weeks prior to screening and likely to cooperate and take part successfully in the study assessments exclusion criteria: * subjects with dsm-iv axis i and ii psychiatric disorders, except those authorized in the inclusion criteria * subjects who may not be able to comply with the protocol or perform the outcome measures due to significant hearing or visual impairment * subjects with evidence of dementia or meeting clinical diagnosis for dementia * subjects with thyroid dysfunction or diabetes that is not adequately controlled and stabilized on treatment for at least 8 weeks prior to randomization